Literature DB >> 21562609

Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma.

Changxue Lu1, Alok Mishra, Yuelin J Zhu, Paul Meltzer, Sheue-Yann Cheng.   

Abstract

Metastasis is the major cause of thyroid cancer-related death. However, little is known about the genes involved in the metastatic spread of thyroid carcinomas. We have created a mouse that spontaneously develops metastatic follicular thyroid carcinoma (FTC). This mouse harbors a targeted mutation (denoted TRβPV) in the thyroid hormone receptor β gene (Thrb(PV/PV) mice). Our recent studies show that the highly elevated level of thyroid stimulating hormone (TSH) in Thrb(PV/PV) mice promotes proliferation of thyroid tumor cells, but requires the collaboration of the oncogenic action of TRβPV to empower the tumor cells to undergo distant metastasis. To uncover genes destined to drive the metastatic process, we used cDNA microarrays to compare the genomic expression profile of laser capture microdissected thyroid tumor lesions of Thrb(PV/PV) mice with that of hyperplastic thyroid cells of wild-type mice having elevated TSH induced by treatment with the anti-thyroid drug propylthiouracil (WT-PTU mice). Analyses of microarray data indicated that the expressions of 150 genes were significantly altered between Thrb(PV/PV) and WT-PTU mice (87 genes had higher expression and 63 genes had lower expression in Thrb(PV/PV) mice than in WT-PTU mice). Thirty-six percent of genes with altered expression function as key regulators in metastasis. The remaining genes were involved in various cellular processes including metabolism, intracellular trafficking, transcriptional regulation, post-transcriptional modification, and cell-cell/extracellular matrix signaling. The present studies have uncovered novel genes responsible for the metastatic spread of FTC and, furthermore, have shown that the metastatic process of thyroid cancer requires effective collaboration among genes with diverse cellular functions. Importantly, the present studies indicate that the tumor cells in the primary lesions are endowed with the genes destined to promote metastasis. Thus, our study has provided new insights into the understanding of the metastatic spread of human thyroid cancer.

Entities:  

Year:  2011        PMID: 21562609      PMCID: PMC3090007     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  37 in total

1.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

Authors:  Akira Tsuchiya; Michiie Sakamoto; Jun Yasuda; Makoto Chuma; Tsutomu Ohta; Misao Ohki; Toshiharu Yasugi; Yuji Taketani; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines.

Authors:  S Hoffmann; K Maschuw; I Hassan; B Reckzeh; A Wunderlich; S Lingelbach; A Zielke
Journal:  Thyroid       Date:  2005-09       Impact factor: 6.568

3.  Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.

Authors:  Xinjiang Yan; Zhipeng Su; Jing Zhang; Zhebao Wu; Sheng Ye; Xianghe Lu; Jinsen Wu; Yanjun Zeng; Weiming Zheng
Journal:  Cell Immunol       Date:  2010-03-27       Impact factor: 4.868

4.  Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma.

Authors:  Wu-Ling Zhu; Bing-Lin Fan; Dong-Liang Liu; Wen-Xiao Zhu
Journal:  Anticancer Res       Date:  2009-07       Impact factor: 2.480

5.  Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.

Authors:  Changxue Lu; Li Zhao; Hao Ying; Mark C Willingham; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2010-02-04       Impact factor: 4.736

6.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

7.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.

Authors:  Celine J Guigon; Li Zhao; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

9.  Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.

Authors:  Takeshi Shimamura; Toshio Fujisawa; Syed R Husain; Bharat Joshi; Raj K Puri
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 13.801

Review 10.  Deubiquitylating enzymes and disease.

Authors:  Shweta Singhal; Matthew C Taylor; Rohan T Baker
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

View more
  4 in total

1.  Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.

Authors:  C Lu; X Zhu; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2011-09-12       Impact factor: 9.867

2.  Genomic aberrations in an African American colorectal cancer cohort reveals a MSI-specific profile and chromosome X amplification in male patients.

Authors:  Hassan Brim; Edward Lee; Mones S Abu-Asab; Mohamed Chaouchi; Hadi Razjouyan; Hassanzadeh Namin; Ajay Goel; Alejandro A Schäffer; Hassan Ashktorab
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

3.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

4.  Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Authors:  Giuseppe Matullo; Simonetta Guarrera; Marta Betti; Giovanni Fiorito; Daniela Ferrante; Floriana Voglino; Gemma Cadby; Cornelia Di Gaetano; Fabio Rosa; Alessia Russo; Ari Hirvonen; Elisabetta Casalone; Sara Tunesi; Marina Padoan; Mara Giordano; Anna Aspesi; Caterina Casadio; Francesco Ardissone; Enrico Ruffini; Pier Giacomo Betta; Roberta Libener; Roberto Guaschino; Ezio Piccolini; Monica Neri; Arthur W B Musk; Nicholas H de Klerk; Jennie Hui; John Beilby; Alan L James; Jenette Creaney; Bruce W Robinson; Sutapa Mukherjee; Lyle J Palmer; Dario Mirabelli; Donatella Ugolini; Stefano Bonassi; Corrado Magnani; Irma Dianzani
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.